Literature DB >> 27793869

Example of the drug interaction between ciclosporin and orlistat, resulting in relapse of Evan's syndrome.

Irina Earnshaw1, Jecko Thachil1.   

Abstract

A man aged 35 years with a history of Evan's syndrome presented to the clinic with jaundice and shortness of breath, with further testing indicating a relapse of his previously well-controlled condition, for which he was taking ciclosporin. This followed shortly after he had started taking orlistat to prevent weight gain from a course of steroids, and once the orlistat was stopped, his platelets began to rise. The patient required 4 months of steroid treatment before his platelet levels finally stabilised and he could be put back on his regular medicine regime. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27793869      PMCID: PMC5093755          DOI: 10.1136/bcr-2016-217246

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes.

Authors:  B Schnetzler; M Kondo-Oestreicher; D Vala; G Khatchatourian; B Faidutti
Journal:  Transplantation       Date:  2000-11-27       Impact factor: 4.939

Review 2.  Mode of action of orlistat.

Authors:  R Guerciolini
Journal:  Int J Obes Relat Metab Disord       Date:  1997-06

3.  Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects.

Authors:  Jianguo Zhi; Rema Moore; Linda Kanitra; Thomas E Mulligan
Journal:  J Clin Pharmacol       Date:  2002-09       Impact factor: 3.126

4.  Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient.

Authors:  H Nägele; B Petersen; U Bonacker; W Rödiger
Journal:  Eur J Clin Pharmacol       Date:  1999-11       Impact factor: 2.953

Review 5.  Management of Evans syndrome.

Authors:  Alice Norton; Irene Roberts
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

6.  Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology.

Authors:  R S EVANS; K TAKAHASHI; R T DUANE; R PAYNE; C LIU
Journal:  AMA Arch Intern Med       Date:  1951-01

7.  Modeling the relationship between drug lipophilicity and potential for an interaction with orlistat.

Authors:  Jianguo Zhi
Journal:  J Clin Pharmacol       Date:  2011-04-19       Impact factor: 3.126

8.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

9.  The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Authors:  J Zhi; A T Melia; R Guerciolini; S G Koss-Twardy; S M Passe; A Rakhit; J A Sadowski
Journal:  J Clin Pharmacol       Date:  1996-07       Impact factor: 3.126

10.  Factors influencing weight gain after renal transplantation.

Authors:  C P Johnson; S Gallagher-Lepak; Y R Zhu; C Porth; S Kelber; A M Roza; M B Adams
Journal:  Transplantation       Date:  1993-10       Impact factor: 4.939

View more
  2 in total

1.  A Case of Evan's Syndrome Induced by Vedolizumab.

Authors:  Henry Jen; Bradley Morganstern; Lionel D'Souza
Journal:  ACG Case Rep J       Date:  2019-02-13

Review 2.  Evans syndrome: clinical perspectives, biological insights and treatment modalities.

Authors:  José Carlos Jaime-Pérez; Patrizia Elva Aguilar-Calderón; Lorena Salazar-Cavazos; David Gómez-Almaguer
Journal:  J Blood Med       Date:  2018-10-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.